Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study
Authors:
- Emanuele CenciniECEmanuele Cencini
- Natale CalominoNCNatale Calomino
- Marta FranceschiniMFMarta Franceschini
- Andreea DragomirADAndreea Dragomir
- Sara FredducciSFSara Fredducci
- Beatrice Esposito VangoneBVBeatrice Esposito Vangone
- Giulia Lucco NaveiGNGiulia Lucco Navei
- Alberto FabbriAFAlberto Fabbri
- Monica BocchiaMBMonica Bocchia
Open Access
- 18 January 2024
- journal article
- research article
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 50-62
Abstract
Mantle cell lymphoma (MCL) prognosis has significantly improved in recent years; however, the possible survival benefit of new treatment options should be evaluated outside of clinical trials. We investigated 73 consecutive MCL patients managed from 2006 to 2020. For younger patients p = 0.04). Interestingly, there was a trend towards improved OS for patients treated between 2016 and 2020 compared to between 2006 and 2010 and between 2011 and 2015 (5-year OS was 91%, 44%, and 33%). These findings could be due to the introduction of BR as a first-line regimen for elderly patients and to the introduction of ibrutinib as a second-line regimen.Keywords
This publication has 47 references indexed in Scilit:
- Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkThe Lancet, 2016
- 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauBritish Journal of Haematology, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Postibrutinib outcomes in patients with mantle cell lymphomaBlood, 2016
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphomaAnnals of Oncology, 2013
- How I treat mantle cell lymphomaBlood, 2009
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2006